Beryl Drugs Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 25	Mar ' 24	Mar ' 23	Mar ' 22	Mar ' 21

Sources of funds

Owner's fund

Equity share capital

5.09

5.09

5.09

5.09

5.09

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

4.41

3.83

2.97

2.20

2.84

Loan funds

Secured loans

4.07

5.09

4.54

5.29

4.34

Unsecured loans

-

-

-

-

-

Total

13.58

14.02

12.61

12.59

12.27

Uses of funds

Fixed assets

Gross block

13.11

11.83

10.64

9.86

9.82

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

6.91

5.67

4.61

3.81

2.49

Net block

6.20

6.17

6.03

6.04

7.33

Capital work-in-progress

-

-

-

-

0.20

Investments

-

-

0.15

0.16

0.12

Net current assets

Current assets, loans & advances

9.76

11.32

11.33

11.62

11.00

Less : current liabilities & provisions

2.38

3.47

4.90

5.24

6.38

Total net current assets

7.38

7.85

6.43

6.39

4.63

Miscellaneous expenses not written

-

-

-

-

-

Total

13.58

14.02

12.61

12.59

12.27

Notes:

Book value of unquoted investments

-

-

-

-

-

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

0.85

0.77

2.02

1.36

1.36

Number of equity sharesoutstanding (Lacs)

50.72

50.72

50.72

50.72

50.72